Rational Combinations 360° Speakers
Roger Dansey, MD
SVP Global Clinical Development Oncology
Merck Research Laboratories
Roger Dansey, MD, joined Merck in January 2015 to lead the company’s late stage oncology development efforts including the recently approved PD-1 inhibitor, Keytruda®. Prior to joining MSD, Dr Dansey was Vice President, Oncology Clinical Research at Gilead Sciences where he led the development of the PI3 kinase delta inhibitor molecule, Zydelig®, to approval in chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular non-Hodgkins lymphoma in both the US and EU. Dr Dansey initially joined the industry working at Amgen, and then moved into clinical roles in Amgen’s oncology and hematology therapeutic area. Dr Dansey received his medical degrees from the University of Witwatersrand, Johannesburg South Africa. Prior to joining industry, he held the position of Associate Professor of Medicine and Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University in Detroit, Michigan.